Daniel J. DeAngelo MD, PhD

Daniel J. DeAngelo, MD, PhD, is Professor of Medicine at Harvard Medical School and Chief of the Division of Leukemia at Dana-Farber Cancer Institute.

Dr. DeAngelo earned his medical degree and doctorate of philosophy in molecular genetics from Albert Einstein College of Medicine. He completed his internship and residency in internal medicine at Massachusetts General Hospital. He subsequently served a clinical fellowship in hematology and oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute, where he joined the staff in 1999.

Dr. DeAngelo is involved with clinical protocols designed to treat patients with de novo or relapsed acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), as well as novel therapeutic approaches for patients with myelodysplasia.

Dr. DeAngelo's current research interests include novel immunotherapeutic approaches to the treatment of AML and myelodysplasia. He currently is developing leukemia tumor vaccines from patients with AML or advanced myelodysplasia and will be assaying for immunological and serological responses.

Dr. DeAngelo is actively involved in a number of professional societies, including the American Society of Hematology and the American Society of Clinical Oncology. He also serves as an ad-hoc reviewer for Therapeutic Advances in Medical Oncology, The New England Journal of Medicine, Blood, American Journal of Hematology, Clinical Cancer Research, Journal of Clinical Oncology, Journal of Gene Medicine, and Leukemia.

Dr. DeAngelo is a member of the NCCN Chronic Myeloid Leukemia Panel and the NCCN Acute Lymphoblastic Leukemia Panel.